Hiraki A, Ueoka H, Yoshino T, Chikamori K, Onishi K, Kiura K, Bessho A, Mimoto J, Date H, Ando A, Shimizu N, Harada M
Second Department of Medicine, Okayama University Medical School, Okayama 700-8558, Japan.
Oncol Rep. 1999 Jan-Feb;6(1):75-80.
Synchronous primary lung cancer (SPLC) occurs in up to 0.5% of patients with lung cancer. Among SPLC cases, coexistence of small cell carcinoma (SCLC) and non-small cell carcinoma has been reported in a very small fraction. Futhermore, there have been no reports discussing treatment and prognosis of SPLC presenting with SCLC and NSCLC. We report on two cases of SPLC presenting SCLC in limited stage and operable NSCLC. One patient developed synchronously SCLC and adenocarcinoma of the lung, while the other SCLC and squamous cell carcinoma of the lung. The clonal origin of these synchronous lung cancers was evaluated using immunohistochemical and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analyses. Both of the patients were diagnosed based on transbronchial lung biopsy (TBLB) and mediastinoscopic biopsy. They were successfully treated with chemoradiotherapy and adjuvant surgery, and are now doing well without any signs of tumor progression for about one year. In both cases, a response of mediastinal lymph node for concurrent chemoradiotherapy was quite different from that of the mass in the lung field. In case 2, p53 mutation was observed in the SCLC tissue, but not in the NSCLC tissue by PCR-SSCP. In both cases, carcinoembryonic antigen was documented in the NSCLC tissue, but not in the SCLC tissue by immunohistochemical staining. This report indicates the importance of the accurate diagnosis of SPLC by employing TBLB and/or media-stinoscopy for the optimal treatment of patients having SPLC presenting with SCLC and NSCLC. Diagnostic criteria and standard treatment of this disease should be established.
同步性原发性肺癌(SPLC)在肺癌患者中的发生率高达0.5%。在SPLC病例中,小细胞癌(SCLC)与非小细胞癌并存的情况报道极少。此外,尚无关于同时出现SCLC和非小细胞肺癌(NSCLC)的SPLC的治疗及预后的报道。我们报告了2例有限期且可手术切除的NSCLC同时合并SCLC的SPLC病例。1例患者同时发生了SCLC和肺腺癌,另1例为SCLC和肺鳞状细胞癌。通过免疫组化和聚合酶链反应-单链构象多态性(PCR-SSCP)分析评估了这些同步性肺癌的克隆起源。2例患者均经支气管肺活检(TBLB)和纵隔镜活检确诊。他们接受了放化疗及辅助手术治疗,目前情况良好,约1年无肿瘤进展迹象。2例患者中,纵隔淋巴结对同步放化疗的反应与肺野肿块的反应截然不同。病例2中,通过PCR-SSCP在SCLC组织中检测到p53突变,而在NSCLC组织中未检测到。2例患者中,通过免疫组化染色在NSCLC组织中检测到癌胚抗原,而在SCLC组织中未检测到。本报告表明,对于同时出现SCLC和NSCLC的SPLC患者,采用TBLB和/或纵隔镜检查进行准确诊断对于优化治疗至关重要。应确立该疾病的诊断标准和规范治疗方法。